3′UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice
- 2 June 2011
- journal article
- Published by American Society of Hematology in Blood
- Vol. 117 (22), 5860-5869
- https://doi.org/10.1182/blood-2011-02-334425
Abstract
Overexpression of high mobility group AT-hook 2 (HMGA2) is found in a number of benign and malignant tumors, including the clonal PIGA− cells in 2 cases of paroxysmal nocturnal hemoglobinuria (PNH) and some myeloproliferative neoplasms (MPNs), and recently in hematopoietic cell clones resulting from gene therapy procedures. In nearly all these cases overexpression is because of deletions or translocations that remove the 3′ untranslated region (UTR) which contains binding sites for the regulatory micro RNA let-7. We were therefore interested in the effect of HMGA2 overexpression in hematopoietic tissues in transgenic mice (ΔHmga2 mice) carrying a 3′UTR-truncated Hmga2 cDNA. ΔHmga2 mice expressed increased levels of HMGA2 protein in various tissues including hematopoietic cells and showed proliferative hematopoiesis with increased numbers in all lineages of peripheral blood cells, hypercellular bone marrow (BM), splenomegaly with extramedullary erythropoiesis and erythropoietin-independent erythroid colony formation. ΔHmga2-derived BM cells had a growth advantage over wild-type cells in competitive repopulation and serial transplantation experiments. Thus overexpression of HMGA2 leads to proliferative hematopoiesis with clonal expansion at the stem cell and progenitor levels and may account for the clonal expansion in PNH and MPNs and in gene therapy patients after vector insertion disrupts the HMGA2 locus.Keywords
This publication has 51 references indexed in Scilit:
- Stem-Cell Gene Therapy for the Wiskott–Aldrich SyndromeNew England Journal of Medicine, 2010
- Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaNature, 2010
- Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1Leukemia, 2010
- DNA Bending by the Mammalian High-Mobility Group Protein AT Hook 2Biochemistry, 2010
- Mutation inTET2in Myeloid CancersNew England Journal of Medicine, 2009
- HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapyNucleic Acids Research, 2009
- Oncogenic HMGA2: short or small?: Figure 1.Genes & Development, 2007
- The tumor suppressor microRNA let-7 represses the HMGA2 oncogeneGenes & Development, 2007
- Disrupting the Pairing Between let-7 and Hmga2 Enhances Oncogenic TransformationScience, 2007
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005